Medical technology firm Trivitron Healthcare and the Centre for Cellular And Molecular Platforms (C-CAMP) on Thursday said they have signed a pact to co-develop healthcare technologies.
The partnership is a strategic step for both Trivitron and C-CAMP, an initiative of the Department of Biotechnology, towards co-development of healthcare technologies completely indigenously under the aegis of 'Joint Intellectual Properties', the partners said in a joint statement.
"The MoU (memorandum of understanding) between C-CAMP and Trivitron would mark a new beginning in the healthcare space with emergence of ground breaking technologies from India developed completely indigenously," C-CAMP Chief Executive Officer and Director Taslimarif Saiyed said.
The tie-up will not only facilitate the technology but also manufacturing of associated devices taking into consideration the desired cost-effectiveness and requirements for commercial viability, he added.
In similar vein, Trivitron Healthcare Pvt Ltd Chairman and Managing Director G S K Velu said, "As a medical technology company providing affordable healthcare solutions, Trivitron constantly pursues technological innovations to offer superior, and yet cost-effective clinical benefits."
The alliance with C-CAMP is in line with this endeavour and "we are confident that C-CAMP's culture of innovation and excellence will enable us to provide technologically more advanced devices for enhanced diagnosis and treatments".
Trivitron will also work along with C-CAMP to co-develop other relevant technologies and devices in the fields of point-of-care testing, microfluidics, and multiplex detection, which are within the domain of expertise and of strategic interest to Trivitron and C-CAMP, the statement said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
